CMPS
Compass PathwaysCMPS
CMPS
About: Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Employees: 166
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
60% more call options, than puts
Call options by funds: $1.56M | Put options by funds: $974K
44% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 27
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
27% more capital invested
Capital invested by funds: $117M [Q4 2024] → $148M (+$31.4M) [Q1 2025]
10.78% more ownership
Funds ownership: 45.23% [Q4 2024] → 56.01% (+10.78%) [Q1 2025]
4% more funds holding
Funds holding: 131 [Q4 2024] → 136 (+5) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
173%
upside
Avg. target
$29
549%
upside
High target
$45
925%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Josh Schimmer | 173%upside $12 | Overweight Assumed | 27 May 2025 |
HC Wainwright & Co. Patrick Trucchio | 925%upside $45 | Buy Reiterated | 12 May 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 month ago
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Business Wire
1 month ago
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20th, 2025. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the web.
Neutral
Seeking Alpha
1 month ago
COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Steve Schultz - SVP, IR Kabir Nath - CEO Teri Loxam - CFO Guy Goodwin - Chief Medical Officer Steve Levin - Chief Patient Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Athena Chin - TD Cowen Sumant Kulkarni - Canaccord Genuity Patrick Trucchio - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.
Neutral
Business Wire
1 month ago
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business. “We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal phase 3 COMP360 program in treatment resistant depression.” said Kabir.
Neutral
Business Wire
1 month ago
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in.
Neutral
Business Wire
1 month ago
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pat.
Positive
The Motley Fool
1 month ago
Why Compass Pathways Stock Was a Double-Digit Winner This Week
The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can be greeted with notable share price pops.
Neutral
Business Wire
1 month ago
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on t.
Neutral
GlobeNewsWire
2 months ago
This Is a Test From GlobeNewswire
This is a test from GlobeNewswire. Readers are advised to disregard.
Neutral
Business Wire
2 months ago
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 trial for treatment resistant depression (TRD). The final participants are completing pre-dosing activities, including washout from anti-depressant medications, if necessary, and those eligible will receive a dose of either 25 mg of COMP360 or placebo. “We are p.
Charts implemented using Lightweight Charts™